Vivani Medical opened lower at $1.12, compared with its previous close of $1.13. In the last trading session, the stock traded between $0.80 and $1.12. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Vivani Medical is now worth
$ 23.50
Resulting in a loss of
$ 76.50 (76.50%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.16 (-13.89%)
Day High
$1.12
Day Low
$0.80
Day Open
$1.12
Prev Close
$1.13
Volume
13,74,506
1W Return
-8.72%
1M Return
-18.51%
3M Return
-30.30%
6M Return
-18.92%
1Y Return
-31.96%
Market Cap ($ Mn)
88
PE Ratio
-
PB Ratio
6.69
PEG Ratio
-
ROE
-259.94%
ROCE
-96.39%
EPS (TTM)
$-0.07
1 Week
-8.72%
1 Month
-18.51%
3 Months
-30.30%
6 Months
-18.92%
9 Months
-22.16%
Vivani Medical Phase 1 trial matches Wegovy weight loss results
Vivani Medical's Phase 1 SLIM-1 trial showed NPM-139 implant matched Wegovy in weight loss. NPM-139 group lost 0.79% body weight vs 0.82% for Wegovy control group. Zero treatment-related adverse events in NPM-139 group vs five in Wegovy group. Company plans Phase 2 dose-ranging trial in 2027 and collaborates with Novo Nordisk.
TodayVivani Medical Q3 loss narrows to $(0.08); SLIM-1 data due
Vivani Medical reported a Q3FY27 loss of $(0.08) per share, narrowing 27.27% YoY. Net loss widened to $7.3 million from $6.5 million due to higher R&D spending. Cash position decreased to $15.5 million from $20.8 million quarter-on-quarter. Top-line data for the SLIM-1 Phase 1 trial of NPM-139 is expected later this week.
TodayVivani Medical Q2 losses narrow 41% YoY; signs Novo Nordisk deal
Vivani Medical reported Q2 2026 results with an EPS of $(0.07), beating estimates and showing a 41% YoY improvement in losses. The company advanced its NPM-139 implant trial, secured a partnership with Novo Nordisk, and initiated the merger of its Cortigent subsidiary with ClearOne. Cash reserves rose to $20.8 million as operating expenses declined across R&D and G&A lines.
3mo agoVivani Medical to present at Emerging Growth Conference on July 15, 2026
Vivani Medical will present at the Emerging Growth Conference on July 15, 2026, with CEO Adam Mendelsohn delivering a company update. The presentation will cover the company's progress in GLP-1 drug implants. An archived webcast will be available post-event.
4mo agoVivani Medical allows Novo Nordisk to evaluate NPM-139
Vivani Medical entered into an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant for chronic weight management using its NanoPortal technology. The company anticipates initiating a Phase 1 study in mid-2026, comparing NPM-139 with Wegovy injections to assess safety and pharmacokinetics.
4mo agoVivani Medical appoints August Moretti to board as Dr. Dean Baker retires
Vivani Medical appointed August Moretti to its board of directors, while Dr. Dean Baker retired. Moretti will chair the Audit Committee and join the Compensation Committee. The company continues to develop its NanoPortal™ technology and GLP-1 based implants for metabolic diseases.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Vivani Medical is now worth
$ 23.50
Resulting in a loss of
$ 76.50 (76.50%)
Note: Past profits do not guarantee future returns.
